Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BPN14770 PK in Severe Renal Impairment
NCT07012005Phase 1Completed
- Sponsor
- Shionogi & Co., Ltd.
- Start
- Aug 2025
- Primary completion
- Dec 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of zatolmilast in Fragile X syndrome (FXS) and Alzheimer's disease (AD) (2 arms), sponsored by Shionogi & Co., Ltd. Primary endpoints: Maximum Plasma Concentration, Time to Reach Cmax and 1 more. Started Aug 2025; status: completed.
02
Drugs
zatolmilast
03
Conditions
Fragile X syndrome (FXS)Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT07012005.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07012005.